Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180293 | 0.89 | ALDH1A1 (0.46) | ALDH1A1F2CYP2D6KDM4ELMNA | |
| SCHEMBL2446754 | 0.87 | ALDH1A1 (0.43) | ALDH1A1CYP2D6KDM4ELMNAPOLB | |
| SCHEMBL10385453 | 0.87 | ALDH1A1 (0.58) | ALDH1A1KDM4ELMNAPOLBKMT2A | |
| SCHEMBL20300372 | 0.87 | NPC1 (0.56) | ALDH1A1KDM4ELMNAPOLBKMT2A | |
| SCHEMBL20323431 | 0.87 | NPC1 (0.50) | ALDH1A1F2CYP2D6KDM4ELMNA | |
| SCHEMBL1502067 | 0.87 | ALDH1A1 (0.48) | ALDH1A1F2CYP2D6KDM4ELMNA | |
| SCHEMBL20323490 | 0.87 | EPHX2 (0.48) | ALDH1A1F2KDM4ELMNAPOLB | |
| SCHEMBL20323774 | 0.86 | LMNA (0.49) | ALDH1A1F2CYP2D6KDM4ELMNA | |
| SCHEMBL30456557 | 0.86 | NPC1 (0.43) | ALDH1A1F2CYP2D6KDM4ELMNA | |
| SCHEMBL3663436 | 0.86 | ALDH1A1 (0.47) | ALDH1A1F2CYP2D6KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303542-A1 | SOLID FORMS OF A PARP14 INHIBITOR | ABBVIE BIOTECHNOLOGY LTD (BM) | 2023-09-28 | — | — | US | disclosed |
| WO-2023154338-A1 | SOLID FORMS OF A PARP14 INHIBITOR | RIBON THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2017-01-26 | — | — | US | disclosed |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-06-02 | — | — | US | disclosed |
| EP-2970099-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9133154-B2 | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2014164905-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| EP-2256114-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275043-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | ALDH1A1 356/4885F2 4503/4885CYP2D6 3152/4885 |
| US-20160229831-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | ALDH1A1 356/4885F2 4503/4885CYP2D6 3152/4885 |
| US-20230303542-A1 | SOLID FORMS OF A PARP14 INHIBITOR | PARP14, PARP1, PARP11 | ALDH1A1 1909/4885F2 2216/4885CYP2D6 3385/4885 |
| US-20170022180-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | ALDH1A1 356/4885F2 4503/4885CYP2D6 3152/4885 |
| US-20160151369-A1 | SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, PSEN2, CLN6 | ALDH1A1 356/4885F2 4503/4885CYP2D6 3152/4885 |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | ALDH1A1 2118/4885F2 1546/4885CYP2D6 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.